Clinical benefit of palbociclib retreatment after abemaciclib exposure in hormone receptor positive, HER2 negative metastatic breast cancer. - Yu M; Yamashita M; Takada M; Takabatake D; Takahashi M; Kochi M; Uno M; Kondo M; Nagashima T; Fujimoto H; Sakakibara J; Teranaka R; et al. (Scientific reports, 2026)